12 August

Detruzitol - instruction , application reviews

Contents:

1. active substance

2. Product form

3. Composition

4. Indications

5. Contraindications

6. dosage and Administration

7. Side effects

8. Cautions

9. Terms and Conditions of storage

Detruzitol - a drug that can help reduce urinary tract smooth muscle tone.

active substance

Tolterodine (Tolterodine)

Product form

drug is available in the form of hard gelatin capsules, sustained-release 2 mg (capsule size - №4, body and cap blue-green color with the number "2" on the body anddrawing a man on the lid) and 4 mg (capsule size - №3, body and cover of blue with the number "4" on the body and patterned as a man on the lid).Capsules

implemented in blisters to 7 pieces in cardboard packs (1, 4, 7, 12 and 40 in each of blisters).

Composition

Capsules 2 mg

1 caps.

tolterodine tartrate

2 mg

Valium Valium, Surelease E-7-19010 Clear (oleic acid, medium-chain triglycerides, ethyl cellulose), sugar pellets (corn starch, sucrose,).

shell composition: gelatin, titanium dioxide, iron oxide yellow dye, indigo, white ink OpacodeWhiteS-1-7085 (simethicone, titanium dioxide, shellac, propylene glycol).

Capsules 4 mg

1 caps.

tolterodine tartrate

4 mg

Excipients: SureleaseE-7-19010 Clear (medium chain triglycerides, ethyl cellulose, oleic acid), sugar granules (maize starch, sucrose), hypromellose.

shell composition: white ink OpacodeWhiteS-1-7085 (propylene glycol, titanium dioxide, simethicone, shellac), titanium dioxide, indigo carmine, gelatin.

Indications Indications for use Detruzitola is overactive bladder, characterized by mandatory, frequent urination, and frequent urination or urinary incontinence.

Contraindications The drug is contraindicated in the following situations apply:

  • Severe ulcerative colitis.
  • delayed gastric emptying.
  • Myasthenia "gravis".
  • untreatable angle-closure glaucoma.
  • Megacolon.
  • Urinary retention.
  • Hereditary fructose intolerance, sucrase-isomaltase deficiency, glucose-galactose malabsorption.
  • Organic causes mandatory and frequent urge to urinate.
  • childhood.
  • Hypersensitivity to the active component of the drug or excipients.

Detruzitol With caution is prescribed for such pathological conditions as:

  • diaphragmatic hernia of esophageal opening.
  • risk slowing gastric emptying.
  • obstructive disease of the gastrointestinal tract (eg, pyloric stenosis).
  • delays risk of urine caused by severe obstruction of the lower divisions urinary tract.
  • Neuropathy.
  • acquired or congenital prolongation of the interval QT.
  • bradycardia.
  • Cardiovascular disease (arrhythmia, myocardial ischemia, congestive heart failure, cardiomyopathy).
  • Electrolyte disturbances (hypocalcemia, hypomagnesemia, hypokalemia).
  • Renal failure.
  • Liver failure.

Also, the drug is prescribed with caution in pregnant or lactating women, persons taking antiarrhythmics class 1A (procainamide, quinidine) and Class 3 (sotalol, amiodarone).

Dosage and Administration

Detruzitol applied orally.Capsules are taken without regard to meals.The recommended daily dose is 4 mg.Multiplicity of reception - 1 times per day.Dose can be reduced to 2 mg per day, based on individual tolerance tolterodine.

patients taking potent inhibitors of CYP3A4 (as a co-treatment), as well as persons suffering from disorders of the kidneys and liver, analyzed the drug is prescribed in a dose of 2 mg per day.

The capsules should be swallowed whole (crush and chew contraindicated).

Side effects

Reception Detruzitola can trigger the development of such adverse reactions as:

  • Nervous system: confusion, drowsiness, headache, dizziness, anxiety.
  • Gastrointestinal: flatulence, constipation, dyspepsia, dry mouth, abdominal pain, gastroesophageal reflux disease.
  • Immune system: allergic reactions.
  • Urinary system: urinary retention, dysuria.
  • bodies of: dry sclera (xerophthalmia), visual impairment (including disturbance of accommodation), inhibition of release of tear fluid.
  • Infections: Sinusitis.
  • Other: fatigue, hot flushes to the skin complexion.

Side effects identified in post-marketing research:

  • Skin: angioneurotic edema.
  • Digestive system: diarrhea.
  • Nervous system: confusion, memory loss, hallucinations.
  • Immune System: anaphylactic reactions.
  • Cardiovascular system: a feeling of palpitations, tachycardia.
  • Other: peripheral edema.

patients, combining tolterodine with cholinesterase inhibitors, may have worsening symptoms of dementia (hallucinations, disorientation, confusion).

Detruzitolom Overdose is characterized by the following symptoms: difficulty urinating or urinary retention, mydriasis, accommodation disorders, severe agitation, hallucinations, convulsions, tachycardia, respiratory failure.

overdose Treatment includes gastric lavage, activated charcoal and symptomatic therapy.In marked excitation or convulsions prescribed benzodiazepine anxiolytics structure;during hallucinations - physostigmine;respiratory failure - artificial respiration;with urinary retention - catheterization of the bladder;tachycardia - beta-blockers.Mydriasis When the patient is transferred into a dark room, or prescribe pilocarpine (eye drops).Also, with an overdose of taking the necessary measures in connection with prolongation of the QT interval.

Cautions

Women of childbearing age at the time of treatment must use reliable methods of contraception.

Before therapy is necessary to exclude organic causes of mandatory and frequent urge to urinate.

During reception Detruzitola should refrain from potentially hazardous activities that require speed of psychomotor reactions, and high concentration, as well as driving a car, as tolterodine reduces the rate of reaction and cause accommodation disturbances.

Terms and Conditions of storage

Store in a dry, dark and protected from children, at room temperature, no more than +25 ° C.

Shelf life - 2 years.

After the expiration date, the drug taking is strictly prohibited.

Attention!

Product description posted on this page is a supplement and a simplified version of the official version of the annotations to the drug.The information is provided for informational purposes only and is not a guide to self-medication.Before using the product you should consult with a specialist and to get acquainted with the instructions approved by the manufacturer.

Latest Blog Post

Libeksin - instruction , application reviews
August 12, 2017

Contents: 1. release form and pharmacological properties 2. Indications libeksin 3. Instruction libeksin: method of use and dosag...

Lespefril - instruction , application reviews
August 12, 2017

Contents: 1. Product form Lespefrila 2. Indications drug Lespefril 3. Contraindications 4. Guide Lespefrila 5. Sideaction...

Lespeflan - instruction , application reviews
August 12, 2017

Contents: 1. Instruction Lespeflanu: indications for use 2. Instruction Lespeflanu: side effects and contraindications 3. Additio...